---
title: Prevalence of cefixime-resistant Neisseria gonorrhoeae in Melbourne, Australia,
  2021-2022
date: '2024-06-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38877763/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240615180904&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: While ceftriaxone remains the first-line treatment for gonorrhoea, the
  US CDC recommended cefixime as a second-line treatment in 2021. We tested 1176 Neisseria
  gonorrhoeae isolates among clients attending the Melbourne Sexual Health Centre
  in 2021-2022. The prevalence of cefixime resistance was 6.3% (74/1176), azithromycin
  resistance was 4.9% (58/1176) and ceftriaxone resistance was 0% (0/1176). Cefixime
  resistance was the highest among women (16.4%, 10/61), followed ...
disable_comments: true
---
While ceftriaxone remains the first-line treatment for gonorrhoea, the US CDC recommended cefixime as a second-line treatment in 2021. We tested 1176 Neisseria gonorrhoeae isolates among clients attending the Melbourne Sexual Health Centre in 2021-2022. The prevalence of cefixime resistance was 6.3% (74/1176), azithromycin resistance was 4.9% (58/1176) and ceftriaxone resistance was 0% (0/1176). Cefixime resistance was the highest among women (16.4%, 10/61), followed ...